1 / 27

Education in Palliative and End-of-life Care - Oncology

The. EPEC-O. TM. Education in Palliative and End-of-life Care - Oncology. Project. The EPEC-O Curriculum is produced by the EPEC TM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong Foundation.

norah
Télécharger la présentation

Education in Palliative and End-of-life Care - Oncology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The EPEC-O TM Education in Palliative and End-of-life Care - Oncology Project The EPEC-O Curriculum is produced by the EPECTM Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong Foundation.

  2. EPEC – Oncology Education in Palliative and End-of-life Care – Oncology Module 3d Symptoms – Ascites

  3. Malignant ascites . . . • Definition: accumulation of fluid in the abdomen

  4. . . . Malignant ascites Epidemiology • 10% caused by malignancy • 80% of malignant ascites is epithelial: • Ovaries • Endometrium • Breast • Colon • GI tract • Pancreas Runyon, et al. Hepatology, 1998.

  5. . . . Malignant ascites • Impact: dyspnea, early satiety, fatigue, abdominal pain • Prognosis: poor • Mean survival with malignant ascites< 4 months • If chemo-responsive cancer, eg, newly Dx ovarian ca, mean survival = 6 months – 1 year

  6. Key points • Pathophysiology • Assessment • Management

  7. Pathophysiology . . . • Normal physiology: • Intravascular pressure = extravascular pressure • No extravascular fluid accumulation • Ascites: • Fluid influx increases • Fluid outflow decreases • Fluid accumulates

  8. . . . Pathophysiology • Elevated hydrostatic pressure (eg, congestive heart failure, cirrhosis) • Decreased osmotic pressure(eg, nephrotic syndrome, malnutrition) • Fluid production > fluid resorption (infections, malignancy)

  9. Ankle swelling Weight gain Girth Fullness Bloating Discomfort Heaviness Indigestion Nausea Vomiting Reflux Umbilical changes Hemorrhoids Assessment . . . History & symptoms

  10. . . . AssessmentPhysical examination • Bulging flanks • Flank dullness • Shifting dullness • Fluid wave

  11. Extra-abdominal signs of ascites • Enlarged liver • Hernias • Scrotal edema • Lower extremity edema • Abdominal venous engorgement • Flattened, protuberant umbilicus

  12. Diagnostic imaging • If physical exam is equivocal • Detects small amounts of fluid, loculation • ‘Ground Glass’ X-ray • CT scan

  13. Diagnostic paracentesis • Color • Cytology • Cell count • Total protein concentration • Serum-ascites albumin gradient Hoefs J. Lab Clin Med, 1983.

  14. Diagnosing ascites - Summary • Malignant etiology likely when ascitic fluid has: • Blood • Positive cytology • Absolute neutrophil count < 250 cells / ml • Total protein concentration > 25 gm / L • Serum-ascites albumin gradient < 11 gm / L

  15. Management • Goal: to relieve the symptoms • With little or no discomfort: don’t treat • Before intervening, discuss prognosis, benefits, risks

  16. When to treat? • With these symptoms: • Dyspnea • Abdominal pain • Fatigue • Anorexia • Early satiety • Reduced exercise tolerance

  17. Therapeutic options • Dietary restriction • Chemotherapy • Diuretics • Therapeutic paracentesis • Surgery

  18. Dietary management • Sodium and severe fluid restriction • Difficult for patients • Discuss benefits, burdens & other treatment options first

  19. Diuretics • Effective • Well-tolerated • Treatment goals: • Remove only enough fluid to manage the symptoms • Slow & gradual diuresis Pockros J, et al. Gastroenterology, 1992.

  20. Selecting a diuretic • Spironolactone 25 mg – 50 mg / day • Amiloride 5 mg / day • Furosemide 20 mg / day

  21. Precautions with diuretics • Avoid salt substitutes • Evaluate benefits & burdens • Not appropriate in patients with: • Limited mobility • UT flow problems • Poor appetite, poor oral intake • Polypharmacy problems

  22. Diuretic adverse effects • Problems with • Sleep deprivation • Self-esteem • Skin • Safety • Fatigue • Hypotension

  23. Therapeutic paracentesis • Indications: • Respiratory distress • Diuretic failure • Rapid symptomatic relief • Safe • In clinic or home

  24. Patient supine or semirecumbent Select site Cleanse, disinfect skin Insert Attach 3-way connector Evacuate Reposition Therapeutic paracentesis technique

  25. Surgery • Peritoneovenous shunts • Drains ascitic fluid into internal jugular vein • Rarely done • Tenckhoff, other catheters • Local anesthesia • Large volume ascites • Outpatient use Barnett TD, Rubins J. J Vasc Intery Radio, 2002. Burger JA, et al. Ann Oncol, 1997.

  26. Summary . . . • Ascites causes distress in patients with advanced cancer • Rule out nonmalignant causes • Treatment is palliative • Dietary, pharmacological, and interventional options are available

  27. . . . Summary Use comprehensive assessment and pathophysiology-based therapy to treat the cause and improve the cancer experience

More Related